Alaunos Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TCRT | ALGS | TOVX | APVO | ACTU | ATOS | |
|---|---|---|---|---|---|---|
| Market cap | 6.19M | 31.35M | 8.72M | 2.90M | 20.34M | 21.16M |
| P/E (TTM) | — | — | 0.3 | 0.0 | — | — |
| Forward P/E | -3.0 | -1.0 | -1.0 | -0.1 | -0.6 | -0.6 |
| Price/book | 6.9 | 1.0 | 0.7 | 0.3 | 9.0 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −26.83% | −29.30% | −29.63% | −94.72% | −94.06% | −81.29% |
| Today | −3.23% | +5.68% | +4.40% | +0.74% | +5.69% | −9.01% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TCRT news ›AXIA Energia (AXIA) director Abdalla received 2,481,419 shares
Director Abdalla Filho received 2.48M AXIA3 shares via conversion of class C preferred (PNC) shares, a $0 price transaction. Plus members following AXIA got this by push and email at 12:57:10 ET - 3.9s after publication. Abdalla Filho Jose…
Alaunos buys Velaris, raises $350m for lung drugs
An oversubscribed private placement came with the deal. Fairmount led it, with Venrock Healthcare Capital Partners, T Rowe Price Investment Management, Wellington Management, Janus Henderson Investors, BB Biotech, Perceptive Advisors and…
Cytokinetics director Harrington awarded 195 shares
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing Bloom Energy Reports Record Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance WD Reports Fiscal First Quarter…
Alaunos completes approximately $350M private placement
Nasdaq's confirmation is still pending, and delisting remains possible if Alaunos does not evidence compliance in its 2026 annual report. The Velaris merger closed on October 13, 2026, and pending stockholder approval of preferred…
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of…
Aclaris Therapeutics (NASDAQ:ACRS) & Alaunos Therapeutics (NASDAQ:TCRT) Critical Review
Posted by Defense World Staff on Oct 19th, 2026 Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap healthcare companies, but which is the better business? We…
TCRT Stock Explodes As Alaunos Seals Velaris Deal And $350M Raise
Alaunos Therapeutics Inc. surged as stocks have been trading up by 28.83 percent on optimistic immunotherapy pipeline sentiment. TCRT has gone from sleepy biotech to full‑on momentum name in a matter of days. The daily chart shows Alaunos…
Alaunos: Fairmount reports 19.99% ownership stake
Alaunos Therapeutics (TCRT) develops TCR cell therapies and a preclinical obesity drug program, built on its Sleeping Beauty and hunTR TCR discovery platforms. - [SCHEDULE 13D] Alaunos Therapeutics, Inc. Major Shareholder Acquisition (>5%)…
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Velaris Therapeutics, the ninth company launched based on Paragon-discovered assets, is advancing a pipeline built to address growth signaling imbalances that drive pulmonary vascular remodeling in PAH and secondary pulmonary hypertension…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net22
- ir.alaunos.com2
- manilatimes.net2
- markets.businessinsider.com2
- prnewswire.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 37 articles, not a forecast.